Jianzheng Jie

Jianzheng Jie


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
WPWei-Zhao Peng
Wei-Zhao Peng
JLJi-Xi Liu
Ji-Xi Liu
CLChao-Feng Li
Chao-Feng Li
RMRen Ma
Ren Ma
JJJianzheng Jie
Jianzheng Jie
Background: The high prevalence of alternative splicing among genes implies the importance of genomic complexity in regulating normal physiological processes and diseases such as gastric cancer (GC). The standard form of stem cell marker CD44 (CD44S) and its alternatives with additional exons are reported to play important roles in multiple types of tumors, but the regulation mechanism of CD44 alternative splicing is not fully understood. Methods: Here the expression of hnRNPK was analyzed among the Cancer Genome Atlas (TCGA) cohort of GC. The function of hnRNPK in GC cells was analyzed and its downstream targeted gene was identified by chromatin immunoprecipitation and dual luciferase report assay. Finally, effect of hnRNPK and its downstream splicing regulator on CD44 alternative splicing was investigated. Results: The expression of hnRNPK was significantly increased in GC and its upregulation was associated with tumor stage and metastasis. Loss-of-function studies found that hnRNPK could promote GC cell proliferation, migration, and invasion. The upregulation of hnRNPK activates the expression of the splicing regulator SRSF1 by binding to the first motif upstream the start codon (− 65 to − 77 site), thereby increasing splicing activity and expression of an oncogenic CD44 isoform, CD44E (has additional variant exons 8 to 10, CD44v8-v10). Conclusion: These findings revealed the importance of the hnRNPK-SRSF1-CD44E axis in promoting gastric tumorigenesis.

7 February 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
ZSZhi-Gang Sun
Zhi-Gang Sun
SCShao-Xuan Chen
Shao-Xuan Chen
BSBai-Long Sun
Bai-Long Sun
DZDa-Kui Zhang
Da-Kui Zhang
HSHong-Liang Sun
Hong-Liang Sun
JJJianzheng Jie
Jianzheng Jie
BACKGROUND Lymphovascular invasion (LVI) and perineural invasion (PNI) are associated with decreased survival in colorectal cancer (CRC), but its significance in N1c stage remains to be clearly defined. AIM To evaluate LVI and PNI as potential prognostic indicators in N1c CRC. METHODS We retrospectively identified 107 consecutive patients who had CRC with N1c disease radically resected at our hospital. Tumors were reviewed for LVI and PNI by one pathologist blinded to the patients’ outcomes. Disease-free survival (DFS), overall survival (OS) and cancer-specific survival (CSS) were determined using the Kaplan-Meier method, with LVI and PNI prognosis differences determined by multivariate analysis using the Cox multiple hazards model. Results were compared using log-rank test. The receiver operating characteristic (ROC) curve was used to evaluate the prognostic predictive ability. RESULTS The median follow-up time was 63.17 (45.33-81.37) months for DFS, with 33.64% (36/107) of patients experiencing recurrence; 21.5% of tumors were found to be LVI positive and 44.9% PNI positive. The 5-year DFS rate was greater for patients with LVI-negative tumors compared with LVI-positive tumors (74.0% vs 35.6%), and PNI was similar (82.5% vs 45.1%). On multivariate analysis, LVI [hazard ratio (HR) = 3.368, 95% confidence interval (CI): 1.628-6.966, P = 0.001] and PNI (HR = 3.055, 95%CI: 1.478-6.313, P = 0.002) were independent prognostic factors for DFS. All patients could be divided into three groups of patients with different prognosis according to LVI and PNI. The 5-year ROC curve for LVI, PNI and their combination prediction of DFS was 0.646, 0.709 and 0.759, respectively. Similar results were seen for OS and CSS. CONCLUSION LVI and PNI could serve as independent prognostic factors of outcomes in N1c CRC patients. Patients with LVI or PNI should be given more attention during treatment.

21 August 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
ZSZhi-Gang Sun
Zhi-Gang Sun
SCShao-Xuan Chen
Shao-Xuan Chen
BSBai-Long Sun
Bai-Long Sun
DZDa-Kui Zhang
Da-Kui Zhang
DZDing-Rong Zhong
Ding-Rong Zhong
JJJianzheng Jie
Jianzheng Jie
BACKGROUND The number of tumor deposits (TDs) does not play a part in the current tumor node metastasis staging. Negative lymph node (NLN) status is associated with the prognosis of colorectal cancer (CRC), but its clear role in N1c stage remains to be defined. AIM To evaluate the combination of TDs and NLNs as potential prognostic indicators in N1c CRC. METHODS We retrospectively identified 107 consecutive patients who had N1c CRC radically resected at China-Japan Friendship Hospital. The combination of TDs and NLNs was calculated by the formula NLNTD = NLN/(TD + 1). Cutoff values of NLNs and NLNTD were determined using the R package “survminer”. Disease-free survival (DFS), overall survival (OS) and cancer-specific survival (CSS) were determined using the Kaplan-Meier method to assess the impact of NLNTD on prognosis. Results were compared using the log-rank test. RESULTS The median follow-up time was 63.17 (45.33-81.37) months for DFS, with 33.64% (36/107) of patients experiencing recurrence during follow-up. Five-year DFS was 66.0% (57.3%-76.0%). There was no significant difference in prognosis between patients with > 12 and ≤ 12 NLNs (P = 0.058) for DFS. Similar results were seen according to the number of TDs. The definition of NLNTD = NLN/(TD + 1) with a cutoff value of 6 divided patients into two groups with different DFS (P = 0.005). Five-year DFS for patients with NLNTD > 6 was 73.5% (63.6%-85.0%), compared with 50.0% (35.7%-70.0%) for those with NLNTD ≤ 6. These two groups had different prognosis without perineural invasion (P = 0.012) or lymphovascular invasion (P = 0.002) even neither (P = 0.053). Similar results were seen for OS and CSS. CONCLUSION NLNTD could serve as important prognostic factor for outcomes in N1c CRC patients. These patients could be stratified for prognosis through NLNTD and the high-risk should be given more attention during treatment.


29 May 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JZJincheng Zhang
Jincheng Zhang
YGYantong Guo
Yantong Guo
ZHZhan Hua
Zhan Hua
MLMeng Liu
Meng Liu
TFTao Fu
Tao Fu
ZCZhiqiang Cheng
Zhiqiang Cheng
Purpose: This study evaluated the efficacy of TiaoPi AnChang Decoction (TPACD) against CAPOX-induced adverse reactions (CIARs) and improving survival outcomes in colorectal cancer (CRC) patients receiving CAPOX as adjuvant chemotherapy. This paper presents an interim analysis of the clinical trial, with a primary focus on CIARs. Patients and methods: This was a randomized, double-blind, placebo-controlled trial enrolling high-risk stage II or III CRC patients undergoing CAPOX who were diagnosed with spleen-kidney deficiency syndrome. The study planned to randomly assign 98 patients in a 1:1 ratio to either the TPACD group (30 mL orally, twice daily) or the placebo group (matched placebo). The trial duration spanned 4 chemotherapy cycles (approximately 84 days), during which we assessed the incidence of CIARs (graded via CTCAE), Traditional Chinese Medicine (TCM) syndrome scores, quality of life (QoL, evaluated via EORTC QLQ-C30), peripheral blood immune cell subsets, tumor markers, safety, and survival outcomes. A linear mixed-effects model was applied to adjust for baseline differences. Results: Among 496 screened CRC patients, 108 were randomized into the TPACD group (n = 54) or the placebo group (n = 54). The incidence of overall CIARs was significantly lower in the TPACD group ( P = 0.009), particularly for grade ≥2 CIARs (37.77% vs. 67.70%, P = 0.008). Subgroup analyses revealed that the treatment effect was homogeneous, with no significant interaction observed between the treatment and the variables of age, sex, BMI, tumor size, or TNM stage (all P for interaction >0.05). TPACD administration resulted in improvements in symptoms including fatigue, nausea, vomiting, loss of appetite, and oxaliplatin-induced peripheral neuropathy. However, its efficacy in alleviating myelosuppression, hand-foot syndrome, and pain was limited. Additionally, TPACD improved overall QoL (least squares mean difference (LSMD) −11.71, P < 0.001), attenuated the progression of spleen-kidney deficiency syndrome (LSMD 3.09, P < 0.001), and positively influenced the CD4+/CD8+ ratio (1.91 ± 0.94 vs. 2.64 ± 1.04, P = 0.002). No additional hepatic or renal injury was observed. The predefined endpoints for survival outcomes had not been reached at the time of this analysis. Conclusion: TPACD serves as an effective, safe, well-tolerated, and readily acceptable complementary therapy for CRC patients undergoing CAPOX. Clinical Trial Registration: https://www.chictr.org.cn/index.html , identifier ChiCTR2200065759.

25 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WCWaiian Cheang
Waiian Cheang
ZHZihan Han
Zihan Han
JJJianzheng Jie
Jianzheng Jie
Artificial intelligence (AI) is being increasingly investigated across colorectal cancer (CRC) management, with the potential to improve diagnostic accuracy, support surgical decision-making, and refine prognostic stratification. This review focuses on AI applications within the surgical treatment continuum for CRC, covering endoscopic screening and diagnosis, radiological staging, intraoperative navigation, postoperative complication prediction and prognostic risk stratification. From a surgeon-centered perspective, we critically analyze the gap between model performance and real-world clinical utility, as well as key translational barriers. We believe this review provides a foundation for clinicians and researchers seeking to understand the current state and future potential of AI in CRC surgical care.